2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Status
Withdrawn
1
Unknown
1
Completed
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Prostatic Neoplasms
52
Neoplasm Metastasis
11
Neoplasms
8
Recurrence
7
Prostate Cancer Metastatic
6
Breast Neoplasms
5
Carcinoma, Transitional Cell
4
Stomach Neoplasms
3
Neoplastic Cells, Circulating
3
Metastatic Castration-resistant Prostate Cancer
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms, Castration-Resistant
2
Ovarian Neoplasms
2
Glioblastoma
2
Carcinoma, Squamous Cell
2
Thrombocytosis
1
Testicular Neoplasms
1
Solid Cancer
1
Small Cell Lung Carcinoma
1
Prostate Cancer, Hereditary, 7
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Nonseminomatous germ cell tumor
1
Myeloproliferative Disorders
1
Interventions
Blood Specimen Collection
29
Reverse Transcriptase Polymerase Chain Reaction
7
Flow Cytometry
7
Surgical Procedures, Operative
4
Liquid Biopsy
4
cabazitaxel
3
Trastuzumab
3
Propofol
3
Carboplatin
3
Bevacizumab
3
Standard of Care
2
Spinal Puncture
2
Sevoflurane
2
Positron Emission Tomography Computed Tomography
2
Pirinitramide
2
Neoadjuvant Therapy
2
Morphine
2
Laparoscopy
2
Hematologic Tests
2
Gemcitabine
2
Folfox protocol
2
Epirubicin
2
Drug Therapy
2
Docetaxel
2
Cyclophosphamide
2
Cisplatin
2
Cetuximab
2
Capecitabine
2
Aspirin
2
Anesthesia, General
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Neoplastic Cells, Circulating
×
cabazitaxel
×
Clear all
NCT03101046
2022-02-10
TACTIK
UNICANCER
Phase 2
Completed
40 enrolled
NCT03050866
2021-08-20
CABA-V7
Erasmus Medical Center
Phase 2
Unknown
140 enrolled
NCT02621190
2016-08-17
CARVE
Erasmus Medical Center
Phase 2
Withdrawn